Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 191-194 , March 2003

Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure

  • Takashi Nagai

      Affiliations

    • Department of Internal Medicine, Public Tomioka General Hospital, 2073-1 Tomioka, Gunma, 370-2393, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-274-63-2111
    • ,
  • Makoto Imamura

      Affiliations

    • Department of Internal Medicine, Public Tomioka General Hospital, 2073-1 Tomioka, Gunma, 370-2393, Japan
    • ,
  • Kunihiko Iizuka

      Affiliations

    • Department of Internal Medicine, Public Tomioka General Hospital, 2073-1 Tomioka, Gunma, 370-2393, Japan
    • ,
  • Masatomo Mori

      Affiliations

    • Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, 370-0021, Japan

Received 17 August 2001 ,Revised 2 September 2002 ,Accepted 1 October 2002.

References 

  1. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. Am. J. Physiol. 1995;268:E185–E193
  2. Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diab. Med. 1996;13:S151–S155
  3. Shiling H, Shuya W, Barabara F, et al.  Pancreatic β-cell KATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J. Pharmacol. Exp. Ther. 2000;293:444–452
  4. Sato Y, Nishikawa M, Shinkai H. High performance liquid chromatographic method for quantitation of a new antidiabetic agent in plasma. J. Liquid Chromatogr. 1988;11:3425–3433
  5. Leonald K, Sergio M, Yulia HW, Siva S, James FM. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2000;85:1081–1086
  6. Hanefeld M, Dickinson S, Bouter KP, Guitaro C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care. 2000;23:202–207
  7. Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinnotropic agent nateglinide in healthy subjects. J. Clin. Pharmacol. 1999;39:172–179
  8. Mihara R, Suzuki M, Shima Y, Akiyoshi M, Kondou N, Gonsho A. Pharmacokinetic studies of AY4166 (4)-Metabolism of 14C-AY4166 in rats and dogs. Jpn. Pharmacol. Ther. 1997;25:S219–S228

PII: S0168-8227(02)00242-5

Diabetes Research and Clinical Practice
Volume 59, Issue 3 , Pages 191-194 , March 2003

Article Tools

* Image Usage & Resolution